Newly Diagnosed Multiple Myeloma (NDMM)
6
3
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
18F-Fluciclovine PET/CT in Multiple Myeloma
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients